Table 1.
Results of IHC showing tissue expressions of CTSF, FBLN1, and AKR1B10 in each clinical group in cohort 3.
| Occur/total (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Brain metastasis | Glioma | P | Schwannoma | P | NSCLC without BM | P | Corresponding non-tumour | P | |
| CTSF | |||||||||
| Strong positive | 2/47 (4%) | 0/9 (0%) | 0.013* | 0/5 (0%) | 0.006** | 0/15 (0%) | 0.017* | 0/13 (0%) | 0.005** |
| Positive | 21/47 (45%) | 2/9 (22%) | 0/5 (0%) | 2/15 (13%) | 0/13 (0%) | ||||
| Weak Positive | 13/47 (28%) | 0/9 (0%) | 0/5 (0%) | 3/15 (20%) | 4/13 (31%) | ||||
| Negative | 11/47 (23%) | 7/9 (78%) | 5/5 (100%) | 10/15 (67%) | 9/13 (69%) | ||||
| FBLN1 | |||||||||
| Strong positive | 0/47 (0%) | 0/9 (0%) | 0.001** | 0/5 (0%) | 0.003** | 0/15 (0%) | 0.031* | 0/13 (0%) | 0.224 |
| Positive | 5/47 (11%) | 0/9 (0%) | 0/5 (0%) | 2/15 (13%) | 0/13 (0%) | ||||
| Weak Positive | 30/47 (64%) | 1/9 (11%) | 0/5 (0%) | 4/15 (27%) | 7/13 (54%) | ||||
| Negative | 12/47 (26%) | 8/9 (89%) | 5/5 (100%) | 9/15 (60%) | 6/13 (46%) | ||||
| AKR1B10 | |||||||||
| Strong positive | 5/47 (11%) | 0/9 (0%) | 0.385 | 0/5 (0%) | 0.016* | 0/15 (0%) | 0.323 | 0/13 (0%) | 0.000*** |
| Positive | 19/47 (40%) | 2/9 (22%) | 0/5 (0%) | 5/15 (33%) | 0/13 (0%) | ||||
| Weak Positive | 21/47 (45%) | 6/9 (67%) | 3/5 (60%) | 10/15 (67%) | 0/13 (0%) | ||||
| Negative | 2/47 (4%) | 1/9 (11%) | 2/5 (40%) | 0/15 (0%) | 13/13 (100%) | ||||
Results of immunohistochemistry (IHC) showing tissue expressions of Cathepsin F (CTSF), Fibulin-1 (FBLN1) and Aldo-keto reductase family 1 member B10 (AKR1B10) in each clinical group in cohort 3. Statistical analyses of IHC staining expression between non-small cell lung cancer (NSCLC) brain metastasis (BM) and each control are shown. Corresponding non-tumour is matched with 13 of 15 NSCLC without BM.
*P < 0.05.
**P < 0.01.
***P < 0.001.